Development of [ 18 F]AlF-RESCA-H006 as a Novel Molecular Probe for 5T4 Tumor Imaging and Exploration of Its Application in Pancreatic Adenocarcinoma
Molecular Pharmaceutics · 2025
DOI: 10.1021/acs.molpharmaceut.5c00430 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Jinping Kong und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, School of Basic Medicine, Guizhou Medical University, Guiyang 550009, China. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Adenocarcinoma, Fluorine Radioisotopes, Radiopharmaceuticals. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Natural Science Foundation of Jiangsu Province, Government of Jiangsu Province, Science and Technology Commission of Shanghai Municipality.
Abstract (Originalsprache)
Pancreatic adenocarcinoma (PAAD) is an extremely lethal cancer, making early detection and precise staging essential for extending survival. Upregulation of 5T4 mRNA was detected in bioinformatics analysis using data from the Cancer Genome Atlas and Genotype-Tissue Expression. In the current work, we confirmed the overexpression of 5T4 protein in tumor samples of PAAD compared with the corresponding paraneoplastic tissue. To visualize 5T4 via positron emission tomography (PET) noninvasively, we successfully developed [18F]AlF-RESCA-H006 based on a single-domain antibody fragment. The radiotracer demonstrated high binding affinity toward 5T4 antigens in vitro and remained stable in the final formulation for up to 4 h storage at room temperature. In two preclinical mouse models of pancreatic cancer, [18F]AlF-RESCA-H006 clearly identified the tumor sites, showing a radioactivity accumulation of 2.43 ± 0.46% ID/g in Balb/C mice with BxPC-3 xenografts and 2.88 ± 1.02% ID/g in NCG mice with PANC-1 xenografts. Taken together, [18F]AlF-RESCA-H006 is a promising PET tracer for detecting 5T4 antigen alteration in PAAD. Further investigations are required to assess its defluorination level in higher species and its permeability through the dense extracellular matrix of pancreatic cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology, School of Basic Medicine, Guizhou Medical University, Guiyang 550009, China.
- Cancer Institute, Xuzhou Medical University, 209 Tongshan Road, Xuzhou, Jiangsu 221004, China.
- Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, 99 West Huaihai Road, Xuzhou, Jiangsu 221002, China.
- Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Xuzhou Medical University, 209 Tongshan Road, Xuzhou, Jiangsu 221004, China.
- Institute of Radiation Medicine, Fudan University, Xietu Road 2094, Shanghai 200032, China.
ORCID-Profile: Junbin Han
Förderung
- Natural Science Foundation of Jiangsu Province
- Government of Jiangsu Province
- Science and Technology Commission of Shanghai Municipality
- Ministry of Industry and Information Technology of the People's Republic of China
- Shanghai Municipal Health Commission
- National Natural Science Foundation of China
- Jiangsu Province Capability Improvement Project through Science, Technology and Education
Zitieren
APA
Kong, J., Zhang, H., Tian, R., Ge, W., He, Y., Chen, T., & Han, J. (2025). Development of [ 18 F]AlF-RESCA-H006 as a Novel Molecular Probe for 5T4 Tumor Imaging and Exploration of Its Application in Pancreatic Adenocarcinoma. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c00430
Vancouver
Kong J, Zhang H, Tian R, Ge W, He Y, Chen T, et al. Development of [ 18 F]AlF-RESCA-H006 as a Novel Molecular Probe for 5T4 Tumor Imaging and Exploration of Its Application in Pancreatic Adenocarcinoma. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.5c00430
BibTeX
@article{Kong2025,
author = {Kong, Jinping and Zhang, Huixia and Tian, Ruhua and Ge, Wenjie and He, Yingfang and Chen, Tengxiang and Han, Junbin},
title = {Development of [ 18 F]AlF-RESCA-H006 as a Novel Molecular Probe for 5T4 Tumor Imaging and Exploration of Its Application in Pancreatic Adenocarcinoma},
journal = {Molecular Pharmaceutics},
year = {2025},
doi = {10.1021/acs.molpharmaceut.5c00430}
}
EUVIMED